JulieRaniNangiaMD

Oncology • Houston, TX

Breast Cancer, Hematologic Oncology

Assistant Professor, Medicine, Baylor College of Medicine

Join to view full profile

Dr. Nangia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nangia's full profile

Already have an account?

Office
7200 Cambridge St
Fl 10
Houston, TX 77030
Phone+1 713-798-1750

Fax+1 713-798-4693

Education & Training

Rush University Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2004 - 2007
University of Missouri Kansas City School of MedicineClass of 2004

Certifications & Licensure

TX State Medical License 2010 - 2026
LA State Medical License 2022 - 2023
IL State Medical License 2007 - 2011
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients Start of enrollment: 2004 Sep 01
Completed
Phase 2
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer Start of enrollment: 2007 Dec 01
Completed
Phase 2
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors Start of enrollment: 2013 May 01
Completed
Phase 2
High Dose Vitamin D vs Standard Dose Vitamin D Study Start of enrollment: 2013 Dec 01
Terminated
Phase 2
CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer Start of enrollment: 2014 Jun 01
Terminated
Phase 1
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Start of enrollment: 2020 Dec 18
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

24 citations
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.
Siri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, Jose A Seoane, Lorraine M King
Cancer Cell. 2022-12-12
31 citations
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
Mothaffar F. Rimawi, Polly A. Niravath, Tao Wang, Brent N. Rexer, Andres Forero
Clinical Cancer Research. 2020-02-15
232 citations
TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases
Rachel A. Freedman, Rebecca Gelman, Carey K. Anders, Michelle E. Melisko, Heather A. Parsons
Journal of Clinical Oncology. 2019-03-12

Press Mentions

Know Your Threat for Breast Most CancersOctober 31st, 2022
Debunking Myths About CancerJune 10th, 2022
Olivia Newton-John, 73, Rereleases Vinyl Edition of 1981 Hit Album, ‘Physical:’ Star Is Thriving While Surviving Stage 4 CancerMay 27th, 2022
Join now to see all